Physician
Tri River Family Health Center
Tri River Family Health Center was paid $7.20M by Medicaid between Jan 2018 and Sep 2024, across 100 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 52% of everything it billed.
33Billing provider infoTRI RIVER FAMILY HEALTH CENTER
UXBRIDGE, MA 01569
UXBRIDGE, MA 01569
33aNPI1316985344assigned 06/03/2006
33bProvider typeInternal Medicine Physician
28Total paid$7.20M
24GClaims110,500
24DCodes billed100
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other Internal Medicine Physician providers in Massachusetts
Rank by total paid#9 of 1,270
Median peer was paid$8K
This provider vs. median862×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,693 | $1.10M | |
| 2019 | 22,777 | $1.38M | |
| 2020 | 16,584 | $1.05M | |
| 2021 | 21,994 | $1.41M | |
| 2022 | 23,243 | $1.71M | |
| 2023 | 6,733 | $508K | |
| 2024incomplete | 476 | $43K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 52% | 24,628 | 21,043 | $3.73M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 12% | 5,002 | 4,527 | $892K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.8% | 3,025 | 2,662 | $418K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.5% | 2,665 | 2,522 | $326K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.7% | 2,120 | 2,051 | $263K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.5% | 2,002 | 1,894 | $251K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.2% | 1,824 | 1,670 | $228K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.6% | 1,515 | 1,463 | $190K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 1,039 | 1,015 | $143K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.0% | 1,088 | 1,059 | $142K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.3% | 652 | 644 | $91K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,371 | 1,156 | $62K |
88 more codes
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,142 | $51K |
| 90651 | <1% | 800 | $44K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 475 | $34K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 215 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,958 | $25K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,655 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,745 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 603 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 603 | $17K |
| 90715 | <1% | 1,013 | $16K | |
| 90686 | <1% | 3,873 | $16K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,238 | $15K |
| 99381 | <1% | 79 | $12K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 462 | $12K |
| 90682 | <1% | 475 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 474 | $11K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 63 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 229 | $8K |
| ATP11 | <1% | 897 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,018 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 225 | $7K |
| ATP08 | <1% | 952 | $7K | |
| 0124A | <1% | 130 | $5K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 214 | $5K |
| 83655 | <1% | 400 | $5K | |
| ATP14 | <1% | 458 | $4K | |
| 82728 | <1% | 349 | $4K | |
| ATP17 | <1% | 379 | $4K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,632 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 181 | $3K |
| 87088 | <1% | 434 | $3K | |
| 87081 | <1% | 487 | $3K | |
| ATP03 | <1% | 453 | $3K | |
| 81001 | <1% | 966 | $3K | |
| 0003A | <1% | 53 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 114 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 28 | $2K |
| 84466 | <1% | 192 | $2K | |
| 0071A | <1% | 37 | $2K | |
| 80050 | General health panel | <1% | 104 | $2K |
| 90670 | <1% | 1,460 | $1K | |
| 84439 | <1% | 162 | $1K | |
| 82570 | <1% | 274 | $1K | |
| 0053A | <1% | 30 | $1K | |
| 83540 | <1% | 206 | $1K | |
| 87650 | <1% | 378 | $1K | |
| 82043 | <1% | 190 | $944.32 | |
| 85027 | <1% | 152 | $826.03 | |
| 86803 | <1% | 66 | $766.07 | |
| 82607 | <1% | 53 | $670.40 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 120 | $565.17 |
| 0072A | <1% | 12 | $550.44 | |
| 85018 | <1% | 187 | $411.73 | |
| 90734 | <1% | 638 | $394.10 | |
| 90473 | <1% | 611 | $266.48 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 163 | $238.76 |
| 84153 | <1% | 14 | $210.86 | |
| 86140 | <1% | 45 | $207.54 | |
| 83735 | <1% | 22 | $128.31 | |
| 81002 | <1% | 75 | $73.92 | |
| 90707 | <1% | 13 | $63.50 | |
| 87077 | <1% | 14 | $59.40 | |
| 90474 | <1% | 124 | $50.15 | |
| 81003 | <1% | 28 | $47.15 | |
| ATP10 | <1% | 12 | $35.84 | |
| 85652 | <1% | 13 | $33.60 | |
| 90696 | <1% | 110 | $20.36 | |
| 90633 | <1% | 782 | $20.36 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,175 | $3.15 |
| 90723 | 0% | 849 | $0.00 | |
| 90619 | 0% | 71 | $0.00 | |
| 90680 | 0% | 897 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 2,495 | $0.00 |
| 80053 | Comprehensive metabolic panel | 0% | 1,310 | $0.00 |
| 90697 | 0% | 138 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 590 | $0.00 |
| 91307 | 0% | 82 | $0.00 | |
| 91305 | 0% | 127 | $0.00 | |
| 90716 | 0% | 14 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 17 | $0.00 |
| 80061 | Lipid panel | 0% | 2,997 | $0.00 |
| 90648 | 0% | 1,262 | $0.00 | |
| 80076 | 0% | 247 | $0.00 | |
| 90710 | 0% | 90 | $0.00 | |
| 91312 | 0% | 130 | $0.00 | |
| 91300 | 0% | 105 | $0.00 | |
| 90700 | 0% | 13 | $0.00 | |
| 90685 | 0% | 201 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMULLER, WILLIAM (MEDICAL DIRECTOR)